Sports Nutrition’s Everyday Adoption And Global Distribution Will Transform This Supplement Leader’s Future

Catalysts

About Applied Nutrition

Applied Nutrition develops and manufactures sports nutrition, health and wellness supplements for a broad global consumer base.

What are the underlying business or industry changes driving this perspective?

• Expansion of sports nutrition and supplements into everyday health routines, supported by survey data that 80% of respondents view supplements as a necessity and 64% are choosing gyms over nightclubs, can support volume growth across categories and filter through into higher revenue over time.
• A broad international footprint across more than 85 countries, combined with new entries into Eastern Europe, Latin America, Asia and a developing opportunity in Canada through a large distributor, gives the company multiple levers to grow sales and spread fixed costs, which can support both revenue and EBITDA.
• Scalable in-house manufacturing and logistics, with capacity already geared toward an estimated £200m of sales and planned expansion to roughly £300m capacity plus a large new warehouse, can improve efficiency, support higher utilization and protect gross margin and free cash flow as volumes build.
• A diverse product mix where whey protein represents 19% of sales, plus new formats such as stick packs, capsules, hydration tablets and collagen drinks, can reduce input cost volatility, support pricing power and help maintain gross margin and EBITDA margin resilience.
• Deepening partnerships with major retailers such as Holland & Barrett via a multiyear joint business plan and expanded listings across grocery and High Street, alongside the D2C app and subscription options, broaden distribution channels and can underpin revenue growth and support earnings quality through recurring sales.

Assumptions

This narrative explores a more optimistic perspective on Applied Nutrition compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts. How have these above catalysts been quantified?

• The bullish analysts are assuming Applied Nutrition's revenue will grow by 18.5% annually over the next 3 years.
• The bullish analysts assume that profit margins will increase from 19.7% today to 20.5% in 3 years time.
• The bullish analysts expect earnings to reach £36.6 million (and earnings per share of £0.15) by about January 2029, up from £21.1 million today. The analysts are largely in agreement about this estimate.
• In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 25.1x on those 2029 earnings, down from 30.7x today. This future PE is greater than the current PE for the GB Personal Products industry at 15.7x.
• The bullish analysts expect the number of shares outstanding to remain consistent over the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.54%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• The business is adding large new manufacturing capacity and a new 84,000 square foot warehouse geared to an estimated £300 million of potential sales. If demand growth is slower than expected or key customers under-order, utilization could lag the expanded footprint, putting pressure on gross margin and earnings.
• Whey protein costs in FY '25 were 30% above FY '24 and carriage, logistics and import duties from China were a headwind. While whey is currently 19% of sales and mix is diversified, sustained high input and freight costs across several categories could compress gross margin and reduce free cash flow conversion over time.
• The model relies heavily on B2B distributors and large retail partners across more than 85 countries, including a multiyear joint business plan with Holland & Barrett. Any long-term shift in retailer shelf priorities, weaker sell through or disruption with key distributors could slow revenue growth and weigh on earnings quality.
• The company is increasing exposure to formats such as stick packs, capsules and effervescent tablets and is considering bringing more of this production in-house. If the expected volume ramp in products like hydration tablets, collagen and endurance ranges does not materialize, the payback on £2 million to £2.5 million of factory expansion plus around £2.5 million of new equipment could be extended, affecting returns on invested capital and future net margins.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bullish price target for Applied Nutrition is £2.95, which represents up to two standard deviations above the consensus price target of £2.55. This valuation is based on what can be assumed as the expectations of Applied Nutrition's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of £2.95, and the most bearish reporting a price target of just £2.1.
  
• In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be £178.1 million, earnings will come to £36.6 million, and it would be trading on a PE ratio of 25.1x, assuming you use a discount rate of 7.5%.
  
• Given the current share price of £2.6, the analyst price target of £2.95 is 12.0% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.